

Resource Summary Report

Generated by [NIF](#) on Sep 13, 2026

SK-MEL-3

RRID:CVCL_0550

Type: Cell Line

Proper Citation

RRID:CVCL_0550

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0550

Proper Citation: RRID:CVCL_0550

Description: Cell line SK-MEL-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Cutaneous melanoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:3518877](#), [PMID:6220172](#), [PMID:8755562](#), [PMID:11668190](#), [PMID:12068308](#), [PMID:17260012](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23285177](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-MEL-3

Synonyms: SK-Mel-3, Sk-mel-3, SK-MEL3, SK-Mel3, SKMEL3

Cross References: BTO:BTO_0002132, CLO:CLO_0009044, EFO:EFO_0002333, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-69, BioSample:SAMN03472882, BioSample:SAMN10988234, cancercellines:CVCL_0550,

CancerTools:161918, Cell_Model_Passport:SIDM01105, ChEMBL-Cells:ChEMBL3307449, ChEMBL-Targets:ChEMBL614920, Cosmic:687443, Cosmic:874445, Cosmic:888063, Cosmic:909724, Cosmic:1022286, Cosmic:1047688, Cosmic:1459671, Cosmic:1995636, Cosmic:2159449, Cosmic-CLP:909724, DepMap:ACH-000423, DSMZ:ACC-321, DSMZCellDive:ACC-321, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:909724, GEO:GSM156045, GEO:GSM827519, GEO:GSM887588, GEO:GSM888671, GEO:GSM1670440, IARC_TP53:26114, IGRhCellID:SKMEL3, KCLB:30069, LiGeA:CCLE_928, LINCX_LDP:LCL-1266, NCBI_Iran:C458, PharmacDB:SKMEL3_1397_2019, PRIDE:PXD022992, PRIDE:PXD030304, Progenetix:CVCL_0550, PubChem_Cell_line:CVCL_0550, Wikidata:Q54954057

ID: CVCL_0550

Record Creation Time: 20220427T221546+0000

Record Last Update: 20260913T010044+0000

Ratings and Alerts

No rating or validation information has been found for SK-MEL-3.

No alerts have been found for SK-MEL-3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

D'Ambrosio M, et al. (2026) Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability. Nature cell biology, 28(5), 915.

Chang J, et al. (2025) Antagonistic roles for MITF and TFE3 in melanoma plasticity. Cell reports, 44(4), 115474.

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. Cancer research, 85(9), 1611.

Saamarthy K, et al. (2025) An optimised Bcl-3 inhibitor for melanoma treatment. British journal of pharmacology, 182(11), 2426.

Xu Y, et al. (2024) BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer. The Journal of clinical endocrinology and metabolism.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Takaki EO, et al. (2024) A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(16), 3603.

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T??cell receptors during successful cancer immunotherapy. *Cell*, 186(16), 3333.

Tagore M, et al. (2023) GABA Regulates Electrical Activity and Tumor Initiation in Melanoma. *Cancer discovery*, 13(10), 2270.

Jahid S, et al. (2022) Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer. *Cell reports*, 39(1), 110641.

Deng W, et al. (2019) WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the epithelial-mesenchymal transition. *The Journal of biological chemistry*, 294(14), 5261.